EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Temporal trends in artemisinin partial resistance and other antimalarial drug mutations in Plasmodium falciparum from Kagera region, Northwestern Tanzania, 2021–2023

Alfred Simkin, Salehe S Mandai, Abebe A Fola, Neeva Wernsman Young, Jacob Marglous, Dativa Pereus, Catherine Bakari, Rashid A Madebe, Misago D Seth, Rule B Mrengela, Angelina J Kisambale, Gervas A Chacha und 15 weitere

Frontiers in Genetics · 03.06.2026 · 17

DOI: 10.3389/fgene.2026.1776108 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Genetics, online erschienen am 03.06.2026. Verfasst von Alfred Simkin und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artemisinin-based combination therapies (ACTs) remain the cornerstone of malaria treatment, yet the emergence of artemisinin partial resistance (ART-R) in Africa threatens their efficacy. ART-R is primarily associated with mutations in Plasmodium falciparum kelch13 (K13), notably R561H, which has been linked to delayed parasite clearance in East Africa. We genotyped 2,866 P. falciparum isolates from seven districts in Tanzania’s Kagera region (2021–2023) using 121 molecular inversion probes (MIP) targeting key resistance loci to characterize trends in ART-R and other resistance markers. The WHO-validated K13 mutation R561H persisted in border districts of Karagwe and Kyerwa, with prevalence ranging from 14% to 26%, and appeared for the first time in Muleba in 2022 (10.0%) and Bukoba rural district (0.7%) in 2023, indicating eastward spread toward Lake Victoria. Regional prevalence of R561H rose from 5.5% in 2021 to 6.9% in 2023. Additional validated (A675V) and candidate (V568G, P441L) mutations were detected at low frequencies. Markers associated with reduced sensitivity to partner drugs showed minimal change. Early DHFR and DHPS mutations were near fixation and high-level resistance markers (DHFR I164L and DHPS A581G) exhibited marked gradients. These latest mutations are significantly spatially colocalized (weighted spearman R 2 = 0.58, P = 0.045) and co-occur within a number of individual genomes. These results highlight notable variation in mutation prevalence and underscore the importance of high-resolution surveillance to identify emerging hotspots and guide targeted interventions. Sustained molecular monitoring is critical to inform treatment policy, preserve ACT efficacy, and mitigate the risk of widespread resistance across East Africa.

Schlagwörter

Stichwörter der Autor:innen

Plasmodium falciparumTanzaniaartemisiningenomicskelchmalariaresistancesurveillance

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, United States.
  • Ifakara Health Institute, Dar es Salaam, Tanzania.
  • Center for Computational Molecular Biology, Brown University, Providence, RI, United States.
  • National Institute for Medical Research, Dar es Salaam, Tanzania.
  • National Malaria Control Programme, Dodoma, Tanzania.
  • Swiss Tropical Public Health Institute, Dar es Salaam, Tanzania.

Zitieren

APA

Simkin, A., Mandai, S. S., Fola, A. A., Young, N. W., Marglous, J., Pereus, D., Bakari, C., Madebe, R. A., Seth, M. D., Mrengela, R. B., Kisambale, A. J., Chacha, G. A., Mandara, C. I., Francis, F., Mbwambo, D., Garimo, I., Chacky, F., Aaron, S., Lusasi, A., …, & Bailey, J. A. (2026). Temporal trends in artemisinin partial resistance and other antimalarial drug mutations in Plasmodium falciparum from Kagera region, Northwestern Tanzania, 2021–2023. Frontiers in Genetics, 17. https://doi.org/10.3389/fgene.2026.1776108

Vancouver

Simkin A, Mandai SS, Fola AA, Young NW, Marglous J, Pereus D, et al. Temporal trends in artemisinin partial resistance and other antimalarial drug mutations in Plasmodium falciparum from Kagera region, Northwestern Tanzania, 2021–2023. Frontiers in Genetics. 2026;17. doi:10.3389/fgene.2026.1776108

BibTeX
@article{Simkin2026,
  author = {Simkin, Alfred and Mandai, Salehe S and Fola, Abebe A and Young, Neeva Wernsman and Marglous, Jacob and Pereus, Dativa and Bakari, Catherine and Madebe, Rashid A and Seth, Misago D and Mrengela, Rule B and Kisambale, Angelina J and Chacha, Gervas A and Mandara, Celine I and Francis, Filbert and Mbwambo, Daniel and Garimo, Issa and Chacky, Frank and Aaron, Sijenunu and Lusasi, Abdallah and Molteni, Fabrizio and Njau, Ritha J A and Kajange, Stella and Nhiga, Samwel L and Mohamed, Ally and Juliano, Jonathan J and Ishengoma, Deus S and Bailey, Jeffrey A},
  title = {Temporal trends in artemisinin partial resistance and other antimalarial drug mutations in Plasmodium falciparum from Kagera region, Northwestern Tanzania, 2021–2023},
  journal = {Frontiers in Genetics},
  year = {2026},
  volume = {17},
  doi = {10.3389/fgene.2026.1776108}
}
Kostenlos starten →